1. Home
  2. ARAY vs ACET Comparison

ARAY vs ACET Comparison

Compare ARAY & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Accuray Incorporated

ARAY

Accuray Incorporated

N/A

Current Price

$0.15

Market Cap

31.3M

Sector

Health Care

ML Signal

N/A

ACET

Adicet Bio Inc.

N/A

Current Price

$3.23

Market Cap

33.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARAY
ACET
Founded
1990
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.3M
33.5M
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
ARAY
ACET
Price
$0.15
$3.23
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $34.83
AVG Volume (30 Days)
★ 1.9M
195.4K
Earning Date
11-04-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 87.50
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.75
N/A
Revenue Next Year
$2.35
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.46
52 Week High
$1.46
$9.97

Technical Indicators

Market Signals
Indicator
ARAY
ACET
Relative Strength Index (RSI) 39.00 20.08
Support Level $0.12 N/A
Resistance Level $0.29 $9.51
Average True Range (ATR) 0.01 0.31
MACD 0.00 -0.00
Stochastic Oscillator 48.33 5.53

Price Performance

Historical Comparison
ARAY
ACET

About ARAY Accuray Incorporated

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: